What is TBPH stock price today?

TBPH (Theravance Biopharma Inc) stock is trading at $17.23 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is TBPH stock going up or down today?

TBPH stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy TBPH stock now?

The decision to buy TBPH depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is TBPH a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for TBPH based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is TBPH stock overvalued or undervalued?

TBPH currently trades at a P/E ratio of 8.15, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if TBPH is fairly priced.

What is TBPH's P/E ratio?

TBPH has a price-to-earnings (P/E) ratio of 8.15, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is TBPH's market cap?

TBPH (Theravance Biopharma Inc) has a market capitalization of $0.86 billion, making it a small-cap stock.

What is TBPH's price to book ratio?

TBPH trades at a price-to-book (P/B) ratio of 2.89, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does TBPH pay dividends?

TBPH does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is TBPH's dividend yield?

TBPH does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is TBPH stock a good long-term investment?

TBPH's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is TBPH's revenue growth rate?

TBPH has shown revenue growth of 1.4% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, TBPH is profitable with a profit margin of 1.0%. This indicates the company generates 1.0 cents of profit for every dollar of revenue.

What are the risks of investing in TBPH?

Key risks for TBPH include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does TBPH compare to its competitors?

Compare TBPH to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize TBPH's performance and positioning.

What is TBPH's stock price target for 2026?

Our AI model provides price targets for TBPH based on fundamental analysis: Bull case $22.40 (+30%), Base case $19.81 (+15%), Bear case $15.51 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about TBPH?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for TBPH. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is TBPH's next earnings report?

TBPH reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

TBPH - Theravance Biopharma Inc

NYSE * Health Care * Biotechnology

$17.23

+$0.45 (+2.68%)

About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

TBPH Key Statistics

Market Cap

$864.05M

P/E Ratio

8.15

P/B Ratio

2.89

EPS

$2.06

Revenue Growth

+1.4%

Profit Margin

1.0%

Employees

How TBPH Compares to Peers

TBPH has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

TBPH has the highest profit margins in Biotechnology

TBPH has the fastest revenue growth among competitors

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
TBPH(This stock)	$864.05M	8.1	1%	1.0%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Theravance Biopharma Inc Company Information

Headquarters: Cayman Islands
Website: www.theravance.com
Sector: Health Care
Industry: Biotechnology

TBPH - Theravance Biopharma Inc

About Theravance Biopharma Inc

TBPH Key Statistics

How TBPH Compares to Peers

Theravance Biopharma Inc Company Information

TBPH Lician Score

TBPH Financial Snowflake

Upcoming Events for TBPH